Phreesia, Inc. (NYSE:PHR) Shares Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC decreased its holdings in shares of Phreesia, Inc. (NYSE:PHR) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,545 shares of the company’s stock after selling 540 shares during the quarter. Conestoga Capital Advisors LLC’s holdings in Phreesia were worth $1,951,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in PHR. Champlain Investment Partners LLC lifted its stake in shares of Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock worth $57,062,000 after purchasing an additional 97,847 shares in the last quarter. State Street Corp lifted its position in Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after acquiring an additional 88,517 shares in the last quarter. Geode Capital Management LLC grew its position in Phreesia by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after acquiring an additional 55,934 shares in the last quarter. Barclays PLC raised its stake in shares of Phreesia by 83.6% during the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after purchasing an additional 43,225 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of Phreesia by 3.0% during the third quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock valued at $31,495,000 after purchasing an additional 42,973 shares during the period. 92.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on PHR. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of Phreesia in a research note on Friday, January 10th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Robert W. Baird reduced their price target on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. KeyCorp boosted their price objective on Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia has a consensus rating of “Buy” and a consensus target price of $31.15.

Phreesia Stock Performance

Shares of PHR opened at $28.02 on Monday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.90. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The company has a market capitalization of $1.63 billion, a PE ratio of -19.06 and a beta of 0.94. The company’s 50 day moving average price is $25.15 and its 200 day moving average price is $23.31.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. Research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Transactions at Phreesia

In other news, SVP Amy Beth Vanduyn sold 25,447 shares of Phreesia stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $20.93, for a total value of $532,605.71. Following the transaction, the senior vice president now directly owns 93,470 shares in the company, valued at approximately $1,956,327.10. The trade was a 21.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael Weintraub sold 15,152 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $21.01, for a total value of $318,343.52. Following the sale, the director now owns 242,827 shares of the company’s stock, valued at approximately $5,101,795.27. The trade was a 5.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 166,153 shares of company stock worth $4,191,304 in the last 90 days. 5.80% of the stock is owned by insiders.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.